• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Galen Institute

  • Home
  • About Us
    • Mission and History
    • Grace-Marie Turner bio
    • Who was Galen?
  • Activities
    • Core Activities
    • Commentary and Oped Tutorial
    • Our Book
    • Galen Guides
  • Contact Us
  • Major Papers
  • Broadcast Interviews
  • Health Policy Consensus Group

Letter to the Editor of The Wall Street Journal

POSTED BY Galen Institute on April 24, 2001.

Activist groups celebrated when pharmaceutical companies settled a lawsuit last week against a South African law allowing the country to make and buy cheap copies of patented AIDS drugs, as reported in the Journal last week. The South African government won its case on principle, and in the process undermined the very reason that drugs even exist.

One of the most important advantages that the U.S. provides to research industries is strong patent protection. If the pharmaceutical industry loses both its incentive and resources to make the huge investment in research, the citizens of this nation and the world will be worse off.

The research-based pharmaceutical industry relies on intellectual property protection to guard its investment of up to $600 million to develop a single new drug. When the companies cannot protect their patents, fewer of the new miracle drugs that the world both wants and needs will be created.

People who die and suffer from diseases that do not yet have a cure should be chilled by these events. The supply of today’s drugs may become less expensive, but the miracle medicines of tomorrow may never appear, and we will not know the cures, lives, and potential we have lost.

Grace-Marie Arnett
President
Galen Institute

Filed Under: Uncategorized

Primary Sidebar

Our Annual Report

Health Care Choices 20/20:

A Vision for the Future

SEARCH

Categories

  • Brian Blase
  • Consumer-Directed Care
  • Doug Badger
  • Grace-Marie Turner
  • Health Insurance
  • Health Policy Consensus Group
  • Health Savings Accounts
  • Innovation
  • Medicaid
  • Medicare
  • Newsletter
  • ObamaCare
  • Prescription Drugs
  • Published
    • Forbes
    • Fox Business
    • Health Affairs
    • LA Times
    • National Review
    • New York Post
    • RealClearHealth
    • Sun Sentinel
    • The Daily Signal
    • The Heritage Foundation
    • The Hill
    • The New York Times
    • The Wall Street Journal
    • The Washington Times
  • Reform Initiatives
  • State Issues
  • Uncategorized

LATEST NEWSLETTER ISSUES

SUBSCRIBE

Social Media

Like Us On Facebook

Twitter: @galeninstitute

 

Copyright Galen Institute at Donors. © 2023; · Log in